Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.

Abstract This Letter describes the discovery of GSK189254 and GSK239512 that were progressed as clinical candidates to explore the potential of H 3 receptor antagonists as novel therapies for the treatment of Alzheimer’s disease and other dementias. By carefully controlling the physicochemical properties of the benzazepine series and through the implementation of an aggressive and innovative screening strategy that employed high throughput in vivo assays to efficiently triage compounds, the medicinal chemistry effort was able to rapidly progress the benzazepine class of H 3 antagonists through to the identification of clinical candidates with robust in vivo efficacy and excellent developability properties.